Table 1.
Clinical and laboratory characteristics in patients with type 1 and type 2 diabetes at baseline and final visit after combined therapy
| Characteristic | Baseline | After treatment | P value |
|---|---|---|---|
| Type 1 diabetes | |||
| BMI, kg/m2 | 26.5 ± 3.3 | 25.8 ± 3.4 | <0.001 |
| FPG, mmol/L | 11.3 ± 4.8 | 10.5 ± 3.8 | <0.5 |
| Fructosamine, μmol/L | 365 ± 53 | 339 ± 50 | 0.004 |
| HbA1c, % | 8.7 ± 1.3 | 8.7 ± 1.2 | <0.5 |
| LDL cholesterol, mmol/L | 2.6 ± 0.8 | 2.3 ± 0.6 | 0.015 |
| Insulin dose, U/kg/day | 0.73 ± 0.36 | 0.60 ± 0.24 | <0.001 |
| Type 2 diabetes | |||
| BMI, kg/m2 | 31.0 ± 4.4 | 30.7 ± 4.3 | 0.109 |
| FPG, mmol/L | 11.3 ± 3.8 | 9.2 ± 3.5 | 0.001 |
| Fructosamine, μmol/L | 371 ± 41 | 324 ± 41 | <0.001 |
| HbA1c, % | 9.3 ± 0.9 | 8.6 ± 0.9 | 0.002 |
| LDL cholesterol, mmol/L | 2.9 ± 0.7 | 2.4 ± 0.8 | 0.008 |
| Insulin dose, U/kg/day | 0.51 ± 0.24 | 0.42 ± 0.21 | <0.001 |
Notes: The values are expressed as mean ± standard deviation; comparison by paired t-test (two-tailed P value).
Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; LDL, low-density lipoprotein.